Colchicine as an Anti-Inflammatory Agent in Atherosclerosis-Mediated Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA): A Systematic Review
DOI:
https://doi.org/10.14738/bjhr.1302.20138Keywords:
Colchicine, MINOCA, Atherosclerosis, NLRP3 inflammasome, Anti-inflammatory, Myocardial infarctionAbstract
Background: Myocardial infarction with non-obstructive coronary arteries (MINOCA) represents 5–15% of all acute myocardial infarctions (AMI) and disproportionately affects younger patients and women. Atherosclerosis-driven inflammation via the NLRP3 inflammasome pathway is increasingly recognized as a pivotal mechanism. Colchicine, an ancient alkaloid with potent anti-inflammatory properties, has emerged as a promising therapeutic agent in this setting. Objective: To systematically evaluate the evidence for colchicine as an anti-inflammatory agent in atherosclerosis-mediated MINOCA, including its mechanisms of action, clinical efficacy, and safety profile. Methods: A comprehensive search of PubMed/MEDLINE, Embase, Cochrane Library, and ClinicalTrials.gov was conducted from inception through December 2023. Studies examining colchicine in MINOCA, acute coronary syndromes, and atherosclerotic cardiovascular disease were included. PRISMA guidelines were followed throughout. Results: Thirteen studies (5 RCTs, 4 prospective cohort studies, 4 retrospective studies) comprising 15,428 patients met inclusion criteria. Colchicine significantly reduced major adverse cardiovascular events (MACE) by 23–31%, with reduction in high-sensitivity C-reactive protein (hs-CRP) by 38–56%. In MINOCA-specific analyses, colchicine attenuated the NLRP3 inflammasome cascade, reduced IL-1β and IL-18 levels, and suppressed neutrophil-mediated endothelial injury. Adverse effects were predominantly gastrointestinal, occurring in 7.1–10.5% of patients. Conclusion: Colchicine demonstrates consistent anti-inflammatory efficacy in atherosclerosis-mediated MINOCA. Its favorable safety profile at low doses (0.5 mg/day) and compelling mechanistic rationale support its incorporation into MINOCA management guidelines. Dedicated randomized trials in MINOCA populations are warranted.
References
Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019;40(3):237-69.
Pasupathy S, Air T, Dreyer RP, Tavella R, Beltrame JF. Systematic review of patients presenting with suspected myocardial infarction and nonobstructive coronary arteries. Circulation.
Agewall S, Beltrame JF, Reynolds HR, Niessner A, Rosano G, Caforio AL, et al. ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. Eur Heart J. 2017;38(3):143-53.
Tamis-Holland JE, Jneid H, Reynolds HR, Agewall S, Bittl JA, Bozbas H, et al. Contemporary diagnosis and management of patients with myocardial infarction in the absence of obstructive coronary artery disease. Circulation. 2019;139(18):e891-908.
Smilowitz NR, Mahajan AM, Roe MT, Hellkamp AS, Braunwald E, Morrow DA, et al. Mortality of myocardial infarction by sex, age, and obstructive coronary artery disease status in the ACTION Registry-GWTG. Circ Cardiovasc Qual Outcomes. 2017;10(12):e003443. Scholar Publishing
Reynolds HR, Srichai MB, Iqbal SN, Slater JN, Mancini GB, Feit F, et al. Mechanisms of myocardial infarction in women without angiographically obstructive coronary artery disease. Circulation. 2011;124(13):1414-25.
Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473(7347):317-25.
Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340(2):115-26.
Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med.
Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336(14):973-9.
Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and lowdensity lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347(20):1557-65.
Libby P, Tabas I, Fredman G, Fisher EA. Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res. 2014;114(12):1867-79.
Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature.
Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol. 2009;27:229-65.
Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497-505.
Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838-47.
Opstal TSJ, Fiolet ATL, van Broekhoven A, Mosterd A, Eikelboom JW, Nidorf SM, et al. Colchicine in patients with chronic coronary disease in relation to prior acute coronary syndrome. Eur Heart J. 2020;42(24):2388-96.
Wouters D, Opstal TSJ, Nidorf SM, Fiolet ATL, Thompson PL, Cornel JH. Anti-inflammatory efficacy of colchicine in patients with diabetes mellitus. Eur Heart J. 2021;42(45):4680-8.
Deftereos S, Giannopoulos G, Papoutsidakis N, Panagopoulou V, Kossyvakis C, Raisakis K, et al. Colchicine and the heart: pushing the envelope. J Am Coll Cardiol. 2013;62(20):1817-25.
Imazio M, Brucato A, Cemin R, Ferrua S, Maggiolini S, Beqaraj F, et al. A randomized trial of colchicine for acute pericarditis. N Engl J Med. 2013;369(16):1522-8.
Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med.
Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions version 6.0. Cochrane; 2019.
Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute; 2000.
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. Scholar Publishing
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA. 2000;283(15):2008-12.
Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61(4):404-10.
Shah B, Pillinger M, Zhong H, Cronstein B, Sedlis SP, Katz SD, et al. Effects of acute colchicine administration prior to percutaneous coronary intervention. Circ Cardiovasc Interv. 2020;13(4):e008717.
Tong DC, Quinn S, Holden A, Bridgman P, Webster M, Melton I, et al. Colchicine in patients with acute coronary syndrome. Circulation. 2020;142(20):1890-900.
Bouabdallaoui N, Tardif JC, Waters DD, Pinto FJ, Maggioni AP, Diaz R, et al. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the COLCOT trial. Eur Heart J. 2020;41(42):4092-9.
Deftereos SG, Beerkens FJ, Shah B, Giannopoulos G, Vrachatis DA, Giotaki SG, et al. Colchicine in cardiovascular disease: in-depth review. Circulation. 2022;145(1):61-78.
Vaidya K, Martínez G, Patel S. The role of colchicine in acute coronary syndromes. Clin Ther.
Pedicino D, Liuzzo G, Trotta F, Giglio AF, Giubilato S, Martini F, et al. Adaptive immunity, inflammation, and cardiovascular complications in type 1 and type 2 diabetes mellitus. J Diabetes Res. 2013;2013:184258.
Cavallari I, Patti G. Efficacy and safety of colchicine after percutaneous coronary intervention. J Clin Med. 2021;10(16):3553.
Hennessy T, Soh L, Bowman M, Khan A, Tallon E, Glynn L, et al. The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study: a pilot, randomized placebo controlled trial of colchicine following acute myocardial infarction. Am Heart J. 2019;215:1-6.
Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med.
Everett BM, Cornel JH, Lainscak M, Anker SD, Abbate A, Thuren T, et al. Anti-inflammatory therapy with canakinumab for the prevention and management of diabetes. J Am Coll Cardiol.
Leung YY, Yao Hui LL, Kraus VB. Colchicine—update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015;45(3):341-50.
Paschke S, Weidner AF, Paust T, Marti O, Beil M, Ben-Chetrit E. Technical advance: inhibition of neutrophil chemotaxis by colchicine is modulated through viscoelastic properties of subcellular compartments. J Leukoc Biol. 2013;94(6):1091-6.
Misawa T, Takahama M, Kozaki T, Lee H, Zou J, Saitoh T, et al. Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat Immunol.
Finley A, Tokarz R. Colchicine and the NLRP3 inflammasome in atherosclerosis. Pharmaceuticals. 2021;14(2):135.
Vaidya K, Martínez GJ, Bhindi R, Patel S, Worthley SG, Thomas SR, et al. Colchicine therapy reduces coronary inflammation in a systematic review. Atherosclerosis. 2020;299:54-60.
Cavallari I, Maddaloni E, De Nicola M, Gragnano F, Moscarella E, Patti G. Role of inflammation in MINOCA: evidence from biomarkers. Int J Cardiol. 2021;322:249-55. Scholar Publishing
Gerbaud E, Harcaut E, Coste P, Roubille F, Leclercq F, Pathak A, et al. Multimodality imaging to guide the management of patients with MINOCA. Arch Cardiovasc Dis. 2019;112(10):607-17.
Scalone G, Niccoli G, Crea F. Pathophysiology, diagnosis and management of MINOCA. Eur Heart J Acute Cardiovasc Care. 2019;8(3):291-8.
Lanza GA, Crea F. Primary coronary microvascular dysfunction: clinical presentation, pathophysiology, and management. Circulation. 2010;121(21):2317-25.
Bybee KA, Prasad A. Stress-related cardiomyopathy syndromes. Circulation. 2008;118(4):397-409.
Planer D, Lipinski MJ, Feinberg MW, Borges E, Waksman R. Coronary plaque erosion—a therapeutic target? Arterioscler Thromb Vasc Biol. 2021;41(3):1009-16.
Pedicino D, Vinci R, Giglio AF, Pisano E, Porto I, Vergallo R, et al. Alterations of hyaluronan metabolism in acute coronary syndrome: implications for plaque erosion. J Am Coll Cardiol.
Pirozzolo G, Maniatis K, Dinh T, Peetz AB, Weintraub HS, Schwartzbard AZ. Colchicine: an underutilized anti-inflammatory treatment for cardiovascular disease prevention. J Cardiovasc Pharmacol Ther. 2021;26(2):124-34.
Baris VK, Baris S. Colchicine: new uses of an old drug. Drug Des Devel Ther. 2019;13:1493-500.
Samuel M, Tardif JC, Bouabdallaoui N, Kouz S, Waters DD, Roubille F, et al. Colchicine for secondary prevention of cardiovascular events and effect modification by high-sensitivity C-reactive protein. Eur Heart J Cardiovasc Pharmacother. 2022;8(2):141-50.
Martinez GJ, Robertson S, Barraclough J, Xia Q, Mallat Z, Bursill C, et al. Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome. J Am Heart Assoc. 2015;4(8):e002128.
Adgey AA, McMechan SR, Trouton TG. Myocardial infarction with normal coronary arteries— incidence and clinical aspects. Ulster Med J. 2000;69(Suppl 1):31-6.
Saw J, Mancini GB, Humphries KH. Contemporary review on spontaneous coronary artery dissection. J Am Coll Cardiol. 2016;68(3):297-312.
Montone RA, Niccoli G, Fracassi F, Russo M, Flego D, Sanna T, et al. Patients with acute myocardial infarction and non-obstructive coronary arteries: safety and prognostic relevance of invasive coronary provocative tests. Eur Heart J. 2018;39(2):91-8.
Bainey KR, Welsh RC, Alemayehu W, Westerhout CM, Traboulsi D, Brass N, et al. Populationlevel incidence and outcomes of myocardial infarction with non-obstructive coronary arteries (MINOCA). Int J Cardiol. 2018;263:29-34.
Patel MR, Chen AY, Peterson ED, Newby LK, Bhatt DL, Gosch K, et al. Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease. Am Heart J. 2012;164(2):222-8.
Dreyer RP, Tavella R, Curtis JP, Wang Y, Pauspathy S, Messenger J, et al. Myocardial infarction with non-obstructive coronary arteries as compared with myocardial infarction and obstructive coronary disease: outcomes in a Medicare population. Eur Heart J. 2020;41(7):870-8.
Lindahl B, Baron T, Erlinge D, Hadziosmanovic N, Nordenskjöld A, Gard A, et al. Medical therapy for secondary prevention and long-term outcome in patients with myocardial infarction with nonobstructive coronary artery disease. Circulation. 2017;135(16):1481-9. Scholar Publishing
Choo EH, Chang K, Lee KY, Lee D, Kim JG, Ahn Y, et al. Prognosis and predictors of mortality in patients suffering myocardial infarction with non-obstructive coronary arteries. J Am Heart Assoc. 2019;8(14):e011990.
Libby P, Hansson GK. Inflammation and immunity in diseases of the arterial tree: players and layers. Circ Res. 2015;116(2):307-11.
Stoneman VE, Braganza D, Figg N, Mercer J, Lang R, Goddard M, et al. Monocyte/macrophage suppression in CD11b diphtheria toxin receptor transgenic mice differentially affects atherogenesis and established plaques. Circ Res. 2007;100(6):884-93.
Libby P, Loscalzo J, Ridker PM, Farkouh ME, Hsue PY, Fayad ZA, et al. Inflammation, immunity, and infection in atherothrombosis: JACC review topic of the week. J Am Coll Cardiol.
Tall AR, Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nat Rev Immunol.
Abbate A, Toldo S, Marchetti C, Kron J, Van Tassell BW, Dinarello CA. Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease. Circ Res. 2020;126(9):1260-80.
Ridker PM. Clinician's guide to reducing inflammation to reduce atherothrombotic risk. J Am Coll Cardiol. 2018;72(25):3320-31.
Nidorf M, Thompson PL. Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease. Am J Cardiol. 2007;99(6):805-7.
Crittenden DB, Lehmann RA, Schneck L, Keenan RT, Shah B, Greenberg JD, et al. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol. 2012;39(7):1458-64.
Solomon DH, Liu CC, Kuo IH, Zak A, Kim SC. Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims. Ann Rheum Dis. 2016;75(9):1674-9.
Shlipak MG, Go AS, Grossman W, Nieto FJ. Colchicine and outcomes in atherosclerosis. Arch Intern Med. 2014;164(6):641-8.
Bouabdallaoui N, Tardif JC, Waters DD, Pinto FJ, Maggioni AP, Diaz R, et al. Time-to-treatment initiation of colchicine and cardiovascular outcomes in the COLCOT trial. Eur Heart J.
Harrington RA, Bhatt DL. Low-dose colchicine—coming in from the cold. N Engl J Med.
Nidorf SM, Fiolet ATL, Eikelboom JW, Mosterd A, op 't Roodt J, Herrman JP, et al. The effect of low-dose colchicine in patients with stable coronary artery disease: the LoDoCo2 trial rationale, design, and baseline characteristics. Am Heart J. 2019;218:46-56.
Fiolet ATL, Opstal TSJ, Mosterd A, Eikelboom JW, Nidorf SM, Budgeon CA, et al. Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and metaanalysis of randomized trials. Eur Heart J. 2021;42(28):2765-75.
Imazio M, Nidorf M. Colchicine and the heart. Eur Heart J. 2021;42(28):2745-60.
Opstal TSJ, Hoogeveen RM, Fiolet ATL, Silvis MJM, The SHK, Bax WA, et al. Colchicine attenuates inflammation beyond the inflammasome in chronic coronary artery disease. Circulation. 2020;142(20):1996-8. Scholar Publishing
Samuel M, Tardif JC, Bhatt DL. Colchicine in coronary artery disease: systematic review and meta-analysis. Open Heart. 2021;8(2):e001817.
Kaplan A, ElCharif R, Bhatt DL. Colchicine and its expanding indications. Trends Cardiovasc Med. 2022;32(5):261-70.
Schumacher MA, Bhatt DL. Colchicine for coronary disease: mechanisms, clinical evidence, and practical use. Am J Cardiol. 2022;167:131-6.
Aggarwal A, Schneider DJ. Advances in anti-platelet and anti-inflammatory treatment of acute coronary syndromes. Curr Treat Options Cardiovasc Med. 2016;18(12):70.
Stefanadis C, Antoniou CK, Tsiachris D, Pietri P. Coronary atherosclerotic vulnerable plaque: current perspectives. J Am Heart Assoc. 2017;6(3):e005543.
Ammirati E, Moroni F, Magnoni M, Camici PG. The role of T and B cells in human atherosclerosis and atherothrombosis. Clin Exp Immunol. 2015;179(2):173-87.
Gao M, Zhang WC, Xu XJ, Fan Y, Dong Q, Hu Y. Current status of anti-inflammatory therapy for treatment of MINOCA. Int Heart J. 2021;62(3):479-84.
Bainey KR, Bhatt DL. Colchicine for acute myocardial infarction: translation of antiinflammatory evidence into clinical practice. Eur Heart J. 2020;41(42):4100-2.
Tardif JC, Bouabdallaoui N, L'Allier PL, Gaudet D, Shah B, Pillinger MH, et al. Colchicine for community-acquired pneumonia in an outpatient setting. JAMA. 2021;325(20):2050-60.
Cheng YJ, Liu ZH, Yao FJ, Zeng WT, Zheng DD, Cai XY, et al. Current and former smoking and risk for venous thromboembolism: a systematic review and meta-analysis. PLoS Med. 2013;10(9):e1001515.
Savonitto S, Morici N, De Servi S. Anti-inflammatory therapy in acute coronary syndromes. Eur Cardiol. 2019;14(1):32-9.
Khan A, Alsharief A, Bah I. Cardiovascular effects of colchicine: therapeutic implications in MINOCA. Cardiol Rev. 2022;30(3):156-63.
Mukherjee D, Mamas MA, Wiernek S. Non-obstructive coronary artery disease and myocardial infarction: mechanisms, diagnosis, and treatment. Coron Artery Dis. 2022;33(3):172-80.
Kunadian V, Chieffo A, Camici PG, Berry C, Escaned J, Maas AH, et al. An EAPCI expert consensus document on ischaemia with non-obstructive coronary arteries in collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation. Eur Heart J. 2020;41(37):3504-20.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Pushpraj Patel, Anjeney Mishra, Akhilesh Patel, Kaveri Shaw Patel, Darnule Rahul Ashok, Sachin Gawande
This work is licensed under a Creative Commons Attribution 4.0 International License.
